----

|   | (Mark One)                                                                                 |   |
|--------|--------------------------------------------------------------------------------------------|--------|
|   | ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OFTHESECURITIES EXCHANGE ACT OF 1934 |   |
|   |                                                                                       |   |

|   | ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR15(d) OF |   |
|--------|-------------------------------------------------------------|--------|
|   | THE SECURITIES EXCHANGE ACT OF 1934                         |   |

| Delaware                                                       |   | 11-3516358                           |
|----------------------------------------------------------------|--------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |
| 15245 Shady Grove Road, Suite 455 Rockville, MD |   | 20850      |
|-------------------------------------------------|--------|------------|
| (Address of principal executive offices)        |   | (Zip Code) |
| Title of each class                       | Trading Symbol(s) | Name of each exchange on which registered |
|-------------------------------------------|-------------------|-------------------------------------------|
| Common Stock, $0.0001 par value per share | REXN              | Nasdaq Capital Market                     |
| Large Accelerated Filer | ☐ | Accelerated Filer         | ☐ |
|-------------------------|---------|---------------------------|---------|
| Non-Accelerated Filer   | ☑ | Smaller reporting company | ☑ |
|                    |    | Emerging growth company   | ☐ |

----

----

|     |    | Page                                                                                           |
|----------|---------|------------------------------------------------------------------------------------------------|
|     |         |                                                                                           |
| PART III |    | 1                                                                                              |
|     | Item 10 | Directors, Executive Officers, and Corporate Governance                                        | 1 |
|     | Item 11 | Executive Compensation                                                                         | 5 |
|     | Item 12 | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 9 |
|     | Item 13 | Certain Relationships and Related Transactions; and Director Independence                      | 11 |
|     | Item 14 | Principal Accounting Fees and Services                                                         | 11 |
|     |    |                                                                                           |   |
| PART IV  |    |                                                                                           |
|     | Item 15 | Exhibits, Financial Statement Schedules                                                        | 12 |
|     |    |                                                                                           |   |
|     |    | Signatures                                                                                     | 17 |

----

Table of Contents

----

Table of Contents

| Item 10. | Directors, Executive Officers and Corporate Governance. |
|----------|---------------------------------------------------------|

| Name               | Age | Position                                           |
|--------------------|-----|----------------------------------------------------|
| Peter Brandt       | 63  | Chairman of the Board of Directors                 |
| Douglas J. Swirsky | 50  | President and Chief Executive Officer and Director |
| Charles Beever     | 67  | Director                                           |
| Kwang Soo Cheong   | 59  | Director                                           |
| Richard J. Rodgers | 53  | Director                                           |
| Ben Gil Price      | 64  | Director                                           |
| Lara Sullivan      | 47  | Director                                           |

----

Table of Contents

----

Table of Contents

|  | ● | appoints or replaces and oversees our independent auditors and approves all audit engagement fees and terms; |
|--|---------|--------------------------------------------------------------------------------------------------------------|
|  | ● | preapproves all audit (including audit-related) services, internal control-related services and permitted non-audit services (including fees and terms thereof) to be performed for us by our independent auditors; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | ● | reviews and discusses with our management and independent auditors significant issues regarding accounting and auditing principles and practices and financial statement presentations; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | ● | reviews and approves our procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters and the confidential, anonymous submission by our employees of concerns                regarding accounting or auditing matters; and |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | ● | reviews and oversees our compliance with legal and regulatory requirements. |
|--|---------|-----------------------------------------------------------------------------|

----

Table of Contents

| Item 11. | Executive Compensation. |
|----------|-------------------------|

| Name and PrincipalPosition(s)                           |   | Year   |   | Salary($) |    |   | Bonus($) |   |   | OptionAwards($)(1)(2) |   |    | Non-EquityIncentivePlan($) |   |   | All OtherCompensation($) |    |   | Total($) |   |
|---------------------------------------------------------|--------|--------|--------|-----------|---------|--------|----------|--------|--------|-----------------------|--------|---------|----------------------------|--------|--------|--------------------------|---------|--------|----------|--------|
| Douglas J. SwirskyPresident and Chief Executive Officer |   | 2019   |   |      | 425,000 |   |     |   | -      |                  |   |    | -                          |   |   |                     | 212,500 |   |     |   | 13,177 |   |   |   | 650,677 |   |
|                                                    | 2018   |   |   | 359,952   |    |   |     | -      |   |                  |   | 703,977 |                       |   |   | 106,250                  |    |   |     | 14,175 |   |   |   | 1,184,354 |   |
| Ely Benaim (3)Former Chief Medical Officer              |   | 2019   |   |      | 110,000 |   |     |   | 88,000 |                  |   |    | 41,254                     |   |   |                     | -       |   |     |   | 5,775 |   |   |   | 245,029 |   |
|                                                    | 2018   |   |   | 440,000   |    |   |     | -      |   |                  |   | 294,861 |                       |   |   | 100,000                  |    |   |     | 16,500 |   |   |   | 851,361 |   |
| Lisa Nolan (3)Former Chief Business Officer             |   | 2019   |   |      | 262,500 |   |     |   | -      |                  |   |    | 53,630                     |   |   |                     | -       |   |     |   | 59,556 |   |   |   | 375,686 |   |
|                                                    | 2018   |   |   | 335,000   |    |   |     | -      |   |                  |   | 62,999  |                       |   |   | 80,000                   |    |   |     | 16,407 |   |   |   | 494,406 |   |
| (1) | Reflects grant date fair value computed in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718. A discussion of assumptions used in calculating grant date fair value of our                equity awards can be found in Note 11 to the Financial Statements included in this Annual Report. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | The actual value realized by each officer with respect to option awards will depend on the difference between the market value of our common stock on the date the option is exercised and the exercise price. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Dr. Benaim resigned from the Company in March 2019, and Dr. Nolan resigned from the Company in September 2019. For Dr. Nolan, All Other Compensation for 2019 includes $45,000 in payments for post-resignation consulting services. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | ● | a material diminution in his duties or authority inconsistent with his position; |
|--|---------|----------------------------------------------------------------------------------|
|  | ● | a reduction of his salary or target bonus percentage; |
|--|---------|-------------------------------------------------------|
|  | ● | a relocation requiring him to be based at any office that is more than 35 miles from our office at the time of the signing of the agreement; or |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------|
|  | ● | any material breach by the Company of the terms and provisions of the agreement or any other material agreement between Mr. Swirsky and the Company. |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|                    |   | Number of Securities Underlying UnexercisedOptions (#) |   |      |               |   |   |                          |   |
|--------------------|--------|--------------------------------------------------------|--------|-----------|---------------|--------|--------|--------------------------|--------|
| Name               |   | Exercisable                                            |   |      | Unexercisable |   |   | Option ExercisePrice ($) |   |   | Option ExpirationDate |   |
| Douglas J. Swirsky |   |                                                   | 9,982  | (1)  |          |   | 10,851 | (1)                 |   |   | 25.20 |   |   | 1/2/2028 |   |
|                    |   |                                                   | 11,284 | (2)  |          |   | 30,382 | (2)                 |   |   | 13.08 |   |   | 11/14/2028 |   |
| Ely Benaim         |   |                                                   | -      |      |          |   | -      |                     |   |   | - |   |   |   | - |   |
| Lisa Nolan         |   |                                                   | -      |      |          |   | -      |                     |   |   | - |   |   |   | - |   |
| (1) | Represents option award granted under the 2013 Plan on January 2, 2018, which vested 25% on January 2, 2019, and 1/48th of which vested or will vest on the first business day of each month beginning in February 2019 and ending in January                2022. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Represents option award granted under the 2013 Plan on November 14, 2018, which vested 25% on November 14, 2019, and 1/48th of which vested or will vest on the first business day of each month beginning in December 2019 and ending in                November 2022. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Position                                               | Compensation*                                                               |
|--------------------------------------------------------|-----------------------------------------------------------------------------|
| Director                                               | $40,000 per annum, plus an additional $25,000 for the Chairman of the Board |
| Audit Committee (Chair)                                | $15,000 per annum                                                           |
| Audit Committee (Member)                               | $7,500 per annum                                                            |
| Compensation Committee (Chair)                         | $10,000 per annum                                                           |
| Compensation Committee (Member)                        | $5,000 per annum                                                            |
| Nominating and Corporate Governance Committee (Chair)  | $7,500 per annum                                                            |
| Nominating and Corporate Governance Committee (Member) | $3,750 per annum                                                            |
| Business Development Committee (Chair)                 | $10,000 per annum                                                           |
| Business Development Committee (Member)                | $5,000 per annum                                                            |

| * | Paid semi-annually. |
|---|---------------------|

| Name               | Fees Earned OrPaid In Cash ($) | OptionAwards ($)(1) | Total ($) |
|--------------------|--------------------------------|---------------------|-----------|
| Peter Brandt       | 82,500                         | 11,851              | 94,351    |
| Charles Beever     | 58,090                         | 11,851              | 69,941    |
| Kwang Soo Cheong   | 51,250                         | 11,851              | 63,101    |
| Richard J. Rodgers | 60,000                         | 11,851              | 71,851    |
| Ben Gil Price      | 49,803                         | 11,851              | 61,654    |
| Lara Sullivan(2)   | 45,287                         | 41,651              | 86,938    |

----

| (1) | Grant date fair value computed in accordance with FASB ASC Topic 718. The actual value realized with respect to option awards will depend on the difference between the market value of our common stock on the date the option is exercised                and the exercise price. As of December 31, 2019, Mr. Beever, Dr. Cheong and Mr. Brandt each had 11,887 option awards outstanding; Mr. Rodgers had 10,639 option awards outstanding; Dr. Price had 12,943 option awards outstanding; and Dr.                Sullivan had 10,617 option awards outstanding. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Dr. Sullivan joined the Board of Directors in February 2019. |
|-----|--------------------------------------------------------------|

----

Table of Contents

| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. |
|----------|-------------------------------------------------------------------------------------------------|

| Plan category                                              |   |  Number of securities to beissued upon exercise ofoutstanding options,warrants and rights |    |   |  Weighted-average exerciseprice of outstandingoptions, warrantsRights |   |   | Number of securities remainingavailable for future issuance underequity compensation plan(excluding securities reflected incolumn (a)) |   |
|------------------------------------------------------------|--------|------------------------------------------------------------------------------------------------|---------|--------|----------------------------------------------------------------------------|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                            |   | (a)                                                                                            |    |   | (b)                                                                        |   |   | (c)                                                                                                                                    |   |
| Equity compensation plans approved by security holders*    |   |                                                                                           | 204,574 |   |                                                                       | $      | 35.60  |                                                                                                                                   |   |   | 93,882 |   |
| Equity compensation plans not approved by security holders |   |                                                                                           | -       |   |                                                                       |   | -      |                                                                                                                                   |   |   | - |   |
| Total                                                      |   |                                                                                           | 204,574 |   |                                                                       | $      | 35.60  |                                                                                                                                   |   |   | 93,882 |   |
|  | ● | each director and nominee; |
|--|---------|----------------------------|
|  | ● | each named executive officer identified in the Summary Compensation Table; and |
|--|---------|--------------------------------------------------------------------------------|
|  | ● | all current directors and executive officers as a group. |
|--|---------|----------------------------------------------------------|

----

Table of Contents

|                                                                |   | Shares of Rexahn PharmaceuticalsCommon StockBeneficially Owned |   |
|---------------------------------------------------------------------|--------|----------------------------------------------------------------|--------|
| Name of Beneficial Owner                                            |   | Number of Shares                                               |   |   | Percentage |   |
| Directors and Named Executive Officers:                             |   |                                                           |   |   |   |   |
| Douglas J. Swirsky                                                  |   |                                                           | 31,942 | (1)  |   |   | * |   |
| Lisa Nolan                                                          |   |                                                           | 1,936  |   |   |   | * |   |
| Ely Benaim                                                          |   |                                                           | 395    |   |   |   | * |   |
| Peter Brandt                                                        |   |                                                           | 9,600  | (2)  |   |   | * |   |
| Charles Beever                                                      |   |                                                           | 9,266  | (3)  |   |   | * |   |
| Kwang Soo Cheong                                                    |   |                                                           | 8,375  | (4)  |   |   | * |   |
| Richard J. Rodgers                                                  |   |                                                           | 7,102  | (5)  |   |   | * |   |
| Ben Gil Price                                                       |   |                                                           | 4,385  | (6)  |   |   | * |   |
| Lara Sullivan                                                       |   |                                                           | 2,360  | (7)  |   |   | * |   |
| All current executive officers and directors as a group (7 persons) |   |                                                           | 73,050 | (8)  |   |   | 1.8 | % |
| * | Represents less than 1% of the issued and outstanding shares of our common stock as of March 31, 2020. |
|---|--------------------------------------------------------------------------------------------------------|
| (1) | Includes Mr. Swirsky’s options to purchase 27,776 shares of common stock that are currently exercisable or exercisable within 60 days of March 31, 2020. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Includes Mr. Brandt’s options to purchase 8,350 shares of common stock that are currently exercisable or exercisable within 60 days of March 31, 2020. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Includes Mr. Beever’s options to purchase 8,350 shares of common stock that are currently exercisable or exercisable within 60 days of March 31, 2020. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Includes Dr. Cheong’s options to purchase 8,350 shares of common stock that are currently exercisable or exercisable within 60 days of March 31, 2020. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (5) | Includes Mr. Rodgers’ options to purchase 7,102 shares of common stock that are currently exercisable or exercisable within 60 days of March 31, 2020. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (6) | Includes Dr. Price’s options to purchase 3,135 shares of common stock that are currently exercisable or exercisable within 60 days of March 31, 2020. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (7) | Includes Dr. Sullivan’s options to purchase 2,360 shares of common stock that are currently exercisable or exercisable within 60 days of March 31, 2020. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (8) | Includes options to purchase 65,423 shares of common stock that are currently exercisable or exercisable within 60 days of March 31, 2020. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Item 13. | Certain Relationships and Related Transactions, and Director Independence. |
|----------|----------------------------------------------------------------------------|

| Item 14. | Principal Accounting Fees and Services. |
|----------|-----------------------------------------|

|               |   | 2019   |    |   | 2018   |   |
|--------------------|--------|--------|---------|--------|--------|--------|
| Audit Fees1        |   | $      | 236,611 |   |   | $      | 212,541 |   |
| Audit-Related Fees |   |   | -       |   |   |   | - |   |
| Tax Fees           |   |   | -       |   |   |   | - |   |
| All Other Fees     |   |   | -       |   |   |   | - |   |

----

----

Table of Contents

| Item 15. | Exhibits, Financial Statement Schedules. |
|----------|------------------------------------------|

| (a) | The following documents are filed as a part of this Annual Report: |
|-----|--------------------------------------------------------------------|

|   | (1) | The following documents are filed as a part of this Annual Report: |
|--------|-----|--------------------------------------------------------------------|

|   |   | Report of Baker Tilly Virchow Krause, LLP                                             | F-1    |
|--------|--------|---------------------------------------------------------------------------------------|--------|
|   |   |                                                                                  |   |
|   |   | Balance Sheet as of December 31, 2019 and December 31, 2018                           | F-2    |
|   |   |                                                                                  |   |
|   |   | Statement of Operations for the year ended December 31, 2019 and 2018                 | F-3    |
|   |   |                                                                                  |   |
|   |   | Statement of Comprehensive Loss for the year ended December 31, 2019 and 2018         | F-4    |
|   |   |                                                                                  |   |
|   |   | Statement of Stockholders’ Equity for the year ended December 31, 2019 and 2018 | F-5    |
|   |   |                                                                                  |   |
|   |   | Statement of Cash Flows for the year ended December 31, 2019 and 2018                 | F-6    |
|   |   |                                                                                  |   |
|   |   | Notes to the Financial Statements                                                     | F-7    |

|   | (2) | All financial statement schedules have been omitted because they are not applicable or not required or because the information is included elsewhere in the financial statements or the                      Notes thereto. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | See the accompanying Index to Exhibits filed as a part of this Annual Report, which list is incorporated by reference in this Item. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------|

| (b) | See the accompanying Index to Exhibits filed as a part of this Annual Report. |
|-----|-------------------------------------------------------------------------------|
| (c) | Other schedules are not applicable. |
|-----|-------------------------------------|

----

Table of Contents

| 3.1    | Amended and Restated Certificate of Incorporation, filed as Appendix G to the Company’s Definitive Proxy Statement on                    Schedule 14A filed on April 29, 2005, is incorporated herein by reference.                                                                          |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                               |
| 3.2    | Certificate of Amendment of Amended and Restated Certificate of Incorporation, filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K,                    filed on May 5, 2017, is incorporated herein by reference.                                                               |
|   |                                                                                                                                                                                                                                                                                               |
| 3.3    | Certificate of Amendment of Amended and Restated Certificate of Incorporation, filed as Exhibit 3.1 to the Company’s                    Current Report on Form 8-K, filed on August 30, 2018 is incorporated herein by reference.                                                            |
|   |                                                                                                                                                                                                                                                                                               |
| 3.4    | Certificate of Amendment of Amended and Restated Certificate of Incorporation, filed as Exhibit 3.1 to the Company’s Current                    Report on Form 8-K, filed on April 12, 2019, is incorporated herein by reference.                                                            |
|   |                                                                                                                                                                                                                                                                                               |
| 3.5    | Amended and Restated Bylaws, as amended, through March 21, 2014, filed as Exhibit 3.2 to the Company’s Annual Report on Form                    10-K for the year ended December 31, 2013, is incorporated herein by reference.                                                              |
|   |                                                                                                                                                                                                                                                                                               |
| 4.1    | Specimen Certificate for the Company’s Common Stock, par value $.0001 per share, filed as Exhibit 4.3 to the Company’s                    Registration Statement on Form S-8 (File No. 333-129294) filed on October 28, 2005, is incorporated herein by reference. |
|   |                                                                                                                                                                                                                                                                                               |
| 4.2    | Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on November 6,                    2015, is incorporated herein by reference.                                                                                                   |
|   |                                                                                                                                                                                                                                                                                               |
| 4.3    | Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on February 26, 2016, is incorporated                      herein by reference.                                                                                                |
|   |                                                                                                                                                                                                                                                                                               |
| 4.4    | Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on                    September 14, 2016, is incorporated herein by reference.                                                                                                 |
|   |                                                                                                                                                                                                                                                                                               |
| 4.5    | Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on June 7,                    2017, is incorporated herein by reference.                                                                                                       |
|   |                                                                                                                                                                                                                                                                                               |
| 4.6    | Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on October 13,                    2017, is incorporated herein by reference.                                                                                                   |
|   |                                                                                                                                                                                                                                                                                               |
| 4.7    | Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on October 19,                    2018, is incorporated herein by reference.                                                                                                   |
|   |                                                                                                                                                                                                                                                                                               |
| 4.8    | Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on January 25,                    2019, is incorporated herein by reference.                                                                                                   |
|   |                                                                                                                                                                                                                                                                                               |
| *4.9   | Description of Common Stock.                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                               |
| **10.1 | Rexahn Pharmaceuticals, Inc. Stock Option Plan, as amended, filed as Exhibit 4.4 to the Company’s Registration Statement                    on Form S-8 (File No. 333-129294) filed on October 28, 2005, is incorporated herein by reference.                                 |
|   |                                                                                                                                                                                                                                                                                               |
| **10.2 | Form of Stock Option Grant Agreement for Employees, filed as Exhibit 4.5.1 to the Company’s Registration Statement on                    Form S-8 (File No. 333-129294) filed on October 28, 2005, is incorporated herein by reference.                                       |

----

Table of Contents

| **10.3 | Form of Stock Option Grant Agreement for Non-Employee Directors and Consultants, filed as Exhibit 4.5.2 to the Company’s                    Registration Statement on Form S-8 (File No. 333-129294) filed on October 28, 2005, is incorporated herein by reference.                                     |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                          |
| **10.4 | Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan, as amended and restated, filed as Exhibit 10.1 to the Company’s Current                    Report on Form 8-K filed on June 10, 2016, is incorporated herein by reference.                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                          |
| **10.5 | First Amendment to the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan, as amended and restated as of June 9, 2016,                    filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 13, 2017, is incorporated herein by reference.                                              |
|   |                                                                                                                                                                                                                                                                                                                          |
| **10.6 | Form of Stock Option Grant Agreement under the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan filed as Exhibit 10.5 to                    the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 is incorporated herein by reference.                                                       |
|   |                                                                                                                                                                                                                                                                                                                          |
| **10.7 | Form of Restricted Stock Unit Agreement under the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan, filed as Exhibit 10.7                    to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, is incorporated herein by reference.                                                  |
|   |                                                                                                                                                                                                                                                                                                                          |
| **10.8 | Employment Agreement, dated as of January 2, 2018, by and between Rexahn Pharmaceuticals, Inc. and Douglas Swirsky, filed as                    Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 4, 2018 is incorporated herein by reference.                                                  |
|   |                                                                                                                                                                                                                                                                                                                          |
| **10.9 | Amendment to Employment Agreement, dated as of November 14, 2018, by and between Rexahn Pharmaceuticals, Inc. and Douglas                    Swirsky, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 16, 2018 is incorporated herein by reference.                                 |
|   |                                                                                                                                                                                                                                                                                                                          |
| 10.10  | Lease Agreement, dated June 5, 2009, by and between Rexahn Pharmaceuticals, Inc. and The Realty Associates Fund V, L.P.,                    filed as Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2009, is incorporated herein by reference.                     |
|   |                                                                                                                                                                                                                                                                                                                          |
| 10.11  | First Amendment to Lease Agreement, dated as of June 7, 2013, by and between Rexahn Pharmaceuticals, Inc. and SG Plaza                    Holdings, LLC, filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2013, is incorporated herein by reference.        |
|   |                                                                                                                                                                                                                                                                                                                          |
| 10.12  | Second Amendment to Lease Agreement, dated as of July 26, 2014, by and between Rexahn Pharmaceuticals, Inc. and SG Plaza                    Holdings, LLC, filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2014, is incorporated herein by reference. |
|   |                                                                                                                                                                                                                                                                                                                          |
| 10.13  | Third Amendment to Lease Agreement, dated as of May 6, 2015, by and between Rexahn Pharmaceuticals, Inc. and SG Plaza                    Holdings, LLC, filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015, is incorporated herein by reference.         |
|   |                                                                                                                                                                                                                                                                                                                          |
| 10.14  | Fourth Amendment to Lease Agreement, dated as of April 4, 2016, by and between Rexahn Pharmaceuticals, Inc. and SG Plaza                    Holdings, LLC, filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2016, is incorporated herein by reference.      |

----

Table of Contents

| 10.15    | Fifth Amendment to Lease Agreement, dated as of April 13, 2017, by and between Rexahn Pharmaceuticals, Inc. and SG Plaza                    Holdings, LLC, filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017, is incorporated herein by reference.                       |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|     |                                                                                                                                                                                                                                                                                                                                           |
| 10.16    | Sixth Amendment to Lease Agreement, dated as of March 19, 2019, by and between Rexahn Pharmaceuticals, Inc. and SG Plaza                    Holdings, LLC, filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019, is incorporated herein by reference.                      |
|     |                                                                                                                                                                                                                                                                                                                                           |
| 10.17    | Form of Securities Purchase Agreement, dated as of November 6, 2015, by and between Rexahn Pharmaceuticals, Inc. and the                    purchasers identified on the signature pages thereto, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 6, 2015, is incorporated herein by reference.      |
|     |                                                                                                                                                                                                                                                                                                                                           |
| 10.18    | Form of Securities Purchase Agreement, dated as of February 26, 2016, by and between Rexahn Pharmaceuticals, Inc. and the                    purchasers identified on the signature pages thereto, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 26, 2016, is incorporated herein by reference.    |
|     |                                                                                                                                                                                                                                                                                                                                           |
| 10.19    | Form of Securities Purchase Agreement, dated as of September 14, 2016, by and between Rexahn Pharmaceuticals, Inc. and the                    purchasers identified on the signature pages thereto, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 14, 2016, is incorporated herein by reference.  |
|     |                                                                                                                                                                                                                                                                                                                                           |
| 10.20    | Form of Securities Purchase Agreement, dated as of June 6, 2017, by and between Rexahn Pharmaceuticals, Inc. and the                    purchasers identified on the signature pages thereto, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 7, 2017, is incorporated herein by reference.              |
|     |                                                                                                                                                                                                                                                                                                                                           |
| 10.21    | Form of Securities Purchase Agreement, dated as of October 13, 2017, by and between Rexahn Pharmaceuticals, Inc. and the                    purchasers identified on the signature pages thereto, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 13, 2017, is incorporated herein by reference.      |
|     |                                                                                                                                                                                                                                                                                                                                           |
| 10.22    | Form of Securities Purchase Agreement, dated as of October 17, 2018, by and between Rexahn Pharmaceuticals, Inc. and the                    purchasers identified on the signature pages thereto, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 19, 2018, is incorporated herein by reference.      |
|     |                                                                                                                                                                                                                                                                                                                                           |
| ***10.23 | Clinical Trial Collaboration and Supply Agreement, dated August 13, 2018, by and between Merck Sharp & Dohme B.V., and Rexahn Pharmaceuticals,                    Inc., filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018, is incorporated herein by reference. |
|     |                                                                                                                                                                                                                                                                                                                                           |
| ***10.24 | Collaboration and License Agreement, dated as of February 25, 2019, between BioSense Global, LLC and Rexahn Pharmaceuticals, Inc., as filed as                    Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019, is incorporated herein by reference.                         |
|     |                                                                                                                                                                                                                                                                                                                                           |
| 10.25    | Amendment No. 1 to Collaboration and License Agreement, dated as of August 24, 2019, between BioSense Global LLC and Rexahn                    Pharmaceuticals, Inc., filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 29, 2019 is incorporated herein by reference.                                    |

----

Table of Contents

| *23.1  | Consent of Baker Tilly Virchow Krause, LLP, independent registered public accounting firm.                                                                                                                                                                                                                                                                                                              |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                    |
| *24.1  | Power of Attorney.                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                    |
| *31.1  | Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a).                                                                                                                                                                                                                                                                                                        |
|   |                                                                                                                                                                                                                                                                                                                                                                                                    |
| 31.2   | Form 10-K/A Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or                    Rule 15d-14(a).                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                    |
| *32.1  | Certification of Chief Executive Officer of Periodic Report Pursuant to 18 U.S.C. Section 1350.                                                                                                                                                                                                                                                                                                    |
|   |                                                                                                                                                                                                                                                                                                                                                                                                    |
| *101   | The following materials from Rexahn Pharmaceuticals, Inc.’s Annual Report on Form 10-K, formatted in Extensible Business Reporting Language (“XBRL”): (i) Balance Sheet; (ii) Statement of Operations; (iii)                  Statement of Comprehensive Loss; (iv) Statement of Stockholders’ Equity; (v) Statement of Cash Flows; and (vi) Notes to the Financial Statements. |

| * | Previously filed or furnished, as applicable, with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on February 21, 2020. |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ** | Indicates management contract or compensatory plan or arrangement. |
|----|--------------------------------------------------------------------|

| *** | Portions of this exhibit have been omitted in compliance with Item 601 of Regulation S-K. |
|-----|-------------------------------------------------------------------------------------------|

----

Table of Contents

|   | REXAHN PHARMACEUTICALS, INC. |
|--------|------------------------------|
|   | By:                          | /s/ Douglas J. Swirsky |
|   |                              | Douglas J. Swirsky |
|   |                              | Chief Executive Officer and President |

----